首页> 外文期刊>The Journal of respiratory diseases >The clinical benefits usually last for years Allergy immunotherapy:Indications, efficacy, and safety
【24h】

The clinical benefits usually last for years Allergy immunotherapy:Indications, efficacy, and safety

机译:临床益处通常持续数年过敏免疫疗法:适应症,功效和安全性

获取原文
获取原文并翻译 | 示例
           

摘要

Although many effective pharmacological therapies are available for patients with allergies, only allergen-specific immunotherapy has been shown to have significant and long-lasting therapeutic and immunomodulatory effects in the management of allergic rhinitis, allergic asthma, and venom hyper-sensitivity. Standard allergen immunotherapy consists of subcutaneous injections of relevant allergens. It requires a buildup phase during which the dose of the vaccine is increased until a therapeutic (maintenance) level is achieved. This maintenance dose is usually continued for 3 to 5 years, and most patients continue to do well after injections are discontinued. Most patients tolerate immunotherapy well, but local reactions are not uncommon. Immunotherapy should be administered only in a physician s office, because some patients may experience systemic anaphylactic reactions requiring immediate therapy. Even with newer therapies on the horizon, allergen immunotherapy will continue to have an important role in the treatment of allergic diseases.
机译:尽管有许多有效的药理疗法可用于过敏症患者,但只有过敏原特异性免疫疗法在过敏性鼻炎,过敏性哮喘和毒液超敏反应的治疗中具有显着而持久的治疗和免疫调节作用。标准过敏原免疫疗法由相关过敏原的皮下注射组成。它需要建立阶段,在此阶段中疫苗剂量应增加,直到达到治疗(维持)水平为止。该维持剂量通常持续3至5年,并且大多数患者在停药后仍能继续保持良好状态。大多数患者对免疫疗法的耐受性良好,但局部反应并不少见。免疫治疗应仅在医师办公室进行,因为某些患者可能会出现全身过敏反应,需要立即进行治疗。即使即将出现新的疗法,过敏原免疫疗法仍将在过敏性疾病的治疗中继续发挥重要作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号